Spirulina
Spirulina scored 7.0 / 10 (💪 Strong recommend) on the BioHarmony scale as a Substance → Vitamin / Mineral / Nutrient.
Spirulina is dried Arthrospira blue-green algae with real human meta-analytic support: pooled randomized trials show systolic blood pressure falling about 4.6 mmHg and diastolic about 7 mmHg per Machowiec 2021, plus meaningful drops in LDL, triglycerides, and fasting glucose. It is cheap and very safe when sourced clean. The main caveat is microcystin contamination from uncertified producers.
What is Spirulina?
Spirulina is dried blue-green algae, specifically the cyanobacteria Arthrospira platensis and Arthrospira maxima, sold as a deep green powder or pressed tablets and used as both a food and a supplement. It is one of the few cheap supplements with a genuine human-trial record: pooled randomized trials in Machowiec 2021 show systolic blood pressure falling about 4.59 mmHg and diastolic about 7.02 mmHg, and separate meta-analyses show meaningful drops in LDL, triglycerides, and fasting glucose. That cardiometabolic cluster, combined with a benign safety profile and a per-month cost in the $10 to $25 range, is why it lands in strong-recommend territory and sits comfortably above the heavily marketed GLP-1 drugs on a cost-adjusted basis.
What you are actually taking is nutrient-dense biomass. Spirulina is roughly 60 to 70 percent protein by dry weight and carries phycocyanin, gamma-linolenic acid, carotenoids, chlorophyll, B vitamins, and iron. The phycocyanin pigment drives much of the antioxidant and anti-inflammatory activity studied in the lab. The honest framing is that spirulina behaves like a concentrated food that nudges several risk markers at once, not like a single-target drug, and the magnitude of each individual effect is modest. The one thing that can turn a benign food into a real hazard is sourcing, since open-pond product from uncertified producers can pick up microcystin toxins or heavy metals.
Terminology
The terms that matter most for spirulina are the ones that separate the safe, well-studied food from the marketing halo and from the real contamination risk. Knowing that Arthrospira is the actual organism, that microcystins are an extrinsic contamination problem and not something the algae makes, and that most clinical benefit is cardiometabolic will keep you from over-claiming and from buying a risky product.
- Arthrospira: The genus of the cyanobacteria sold as spirulina, mainly Arthrospira platensis and Arthrospira maxima. The marketing name spirulina is older than the current taxonomy.
- Cyanobacteria: Photosynthetic bacteria, historically called blue-green algae. Spirulina is technically a bacterium, not a plant.
- Phycocyanin: The blue pigment-protein in spirulina that carries most of its antioxidant and anti-inflammatory activity.
- GLA: Gamma-Linolenic Acid, an omega-6 fatty acid present in spirulina and linked to anti-inflammatory signaling.
- Microcystins: Liver-toxic compounds made by certain contaminant cyanobacteria. They are a sourcing problem in open-pond product, not a product of Arthrospira itself.
- PKU: Phenylketonuria, a metabolic disorder in which phenylalanine cannot be processed. Spirulina contains phenylalanine and is contraindicated.
- NAFLD: Non-Alcoholic Fatty Liver Disease, a target of some spirulina trials measuring liver enzymes.
- CRP: C-Reactive Protein, a blood marker of inflammation that fell modestly in pooled trials.
- HbA1c: Glycated hemoglobin, a three-month average of blood sugar. Spirulina moves fasting glucose more reliably than HbA1c.
- SMD: Standardized Mean Difference, an effect-size metric used in meta-analyses.
- WMD: Weighted Mean Difference, a pooled effect expressed in the original units such as mmHg.
- COA: Certificate of Analysis, the lab document that verifies a product's identity, potency, and contaminant levels.
How do you take Spirulina?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral powder | Loose dried algae powder | 1 to 8 g/day | 1 to 10 g/day |
| Oral tablet | Compressed tablets, typically 500 mg each | 1 to 8 g/day | 1 to 10 g/day |
Protocols
Blood pressure and lipid support Clinical
- Dose
- 1 to 4.5 g/day
- Frequency
- Daily
- Duration
- 12 weeks minimum to judge effect
Matches the dose range used in the blood-pressure and lipid meta-analyses. Track blood pressure and a lipid panel before and after.
Glycemic and metabolic support Clinical
- Dose
- 2 to 8 g/day
- Frequency
- Daily
- Duration
- 8 to 12 weeks
Glycemic and NAFLD trials cluster in this range. Pair with a fasting glucose check, since the pooled effect is on fasting glucose more than HbA1c.
How this score is calculated →
What are the benefits of Spirulina?
Upside contribution: 2.29
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.3 | 0.825 | |
| Breadth | 15% | 3.7 | 0.555 | |
| Evidence | 25% | 3.4 | 0.850 | |
| Speed | 10% | 2.8 | 0.280 | |
| Durability | 10% | 2.5 | 0.250 | |
| Bioindividuality | 15% | 3.5 | 0.525 | |
| Total | 3.285 |
Upside Rationale
The upside comes from one strong, replicated cluster: cardiometabolic risk factors. The single most citable finding comes from Machowiec 2021, a meta-analysis of randomized trials showing systolic blood pressure down 4.59 mmHg and diastolic down 7.02 mmHg, with the largest effect in people who started hypertensive. Around that sit consistent lipid and glucose meta-analyses. The key boundary condition is that each effect is modest and most sit on surrogate markers, so spirulina is a coherent adjunct to diet, exercise, and medication, not a standalone therapy. The breadth of small simultaneous benefits, the food-grade safety, and the very low cost are what carry the score.
Efficacy (3.3/5.0): The strongest single citable finding is fasting glucose falling 17.88 mg/dL in type 2 diabetics per Hatami 2021, pooling 8 studies. Alongside it, Serban 2016 pooled 7 RCTs and found LDL down 41.32 mg/dL and triglycerides down 44.23 mg/dL, and Machowiec 2021 found blood pressure down several mmHg. These are real, replicated, real-world-relevant magnitudes, which is why efficacy sits above the midpoint. It is held back from the top band because the effects are modest in absolute terms, several rest on surrogate markers rather than hard clinical endpoints, and the antioxidant and inflammation outcomes are inconsistent. Strongest responders are people with elevated baseline blood pressure, lipids, or fasting glucose; healthy normals see less.
Breadth of Benefits (3.7/5.0): Spirulina touches several systems at once with at least one human endpoint each. Cardiovascular: blood pressure down per Machowiec 2021. Metabolic and glycemic: fasting glucose down 17.88 mg/dL and lipids improved per Hatami 2021. Body composition: weight down 1.07 kg per Lak 2025. Inflammation: CRP down 0.55 mg/L in the pooled CRP meta-analysis. Respiratory and allergy: symptom relief in the allergic rhinitis RCT. Exercise: time to fatigue up in small double-blind crossover trials. The scope boundary is that cognition, mood, hormonal, and detox claims lack human support and should not be assumed.
Evidence Quality (3.4/5.0): This is a multi-meta-analysis evidence base, which is unusual for a cheap whole food. Blood pressure has two meta-analyses, lipids have at least two including the GRADE-assessed Rahnama 2023, glycemia has two, and body composition and CRP each have one. That consistent pooled direction across independent teams supports a solid-signal score. It is not higher because individual trials are small and short, some are industry-adjacent, the antioxidant meta-analysis Mohiti 2021 was null, and one NAFLD trial carries an Expression of Concern. Per the real-world-outcome rubric, this gets no penalty for being a non-patentable food, and the centuries of safe dietary use add confidence rather than subtract it.
Speed of Onset (2.8/5.0): Spirulina is a slow, chronic-dosing intervention with no acute effect to feel. The blood-pressure and lipid trials that establish the evidence ran roughly 6 to 12 weeks, and the glycemic and NAFLD trials used 8 to 12 weeks. Allergic rhinitis relief in Cingi 2008 built over several weeks of daily use. The practical benchmark is a 12-week commitment with before-and-after measurement, which keeps speed below the midpoint.
Durability (2.5/5.0): The cardiometabolic effects depend on continued daily dosing, and there is no evidence of a lasting benefit after stopping. Spirulina behaves like a food intervention: the markers improve while you take it and would be expected to drift back toward baseline once you stop, the same pattern seen with most dietary changes. There is no rebound or worsening beyond baseline, but there is also no durable carryover, which places durability in the lower-middle range.
Bioindividuality Upside (3.5/5.0): Response is predictable from baseline. The clearest strong responders are people who start with high blood pressure, since Machowiec 2021 found the effect concentrated in hypertensives, and similarly those with elevated LDL, triglycerides, or fasting glucose. Weak responders are healthy people with already-optimal markers, who have little room to move. This makes spirulina easy to target: pick the marker you want to shift, confirm it is elevated, dose for 12 weeks, and re-measure. That measurability is a genuine bioindividuality advantage over interventions whose effects are diffuse and hard to track.
What are the risks & downsides of Spirulina?
Downside contribution: 0.71 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 1.6 | 0.480 | |
| Side effects | 15% | 1.6 | 0.240 | |
| Cost | 5% | 1.6 | 0.080 | |
| Effort | 5% | 1.6 | 0.080 | |
| Opportunity | 5% | 2.0 | 0.100 | |
| Dependency | 15% | 1.4 | 0.210 | |
| Reversibility | 25% | 1.4 | 0.350 | |
| Total | 1.540 | |||
| Harm subtotal × 1.4 | 1.792 | |||
| Opportunity subtotal × 1.0 | 0.260 | |||
| Combined downside | 2.052 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.712 |
Downside Rationale
The dominant concern with spirulina is not intrinsic toxicity but sourcing. The algae itself is a benign food with a centuries-long use history, so the harm dimensions score low. The people most exposed are those who buy uncertified open-pond product that can carry microcystin toxins or heavy metals, plus the narrow groups with a real intrinsic contraindication: anyone with phenylketonuria and, more cautiously, people with autoimmune disease. Everything else is mild and reversible. Per the spec, the contamination risk is treated as an extrinsic sourcing caveat surfaced in the Verdict and confidence label, not as an inflation of the intrinsic Safety score.
Safety Risk (1.6/5.0): Clean-sourced spirulina is benign, which is why safety sits near the floor. It has been eaten as a food for centuries with no signal of harm from the algae itself, and clinical trials report no serious adverse events at typical doses. The genuinely intrinsic risks are narrow: phenylketonuria is a hard contraindication because spirulina contains phenylalanine, and autoimmune disease warrants caution because immune stimulation could theoretically provoke a flare. The contamination findings in Rhoades 2023 are real but extrinsic, a property of open-pond production and contaminant cyanobacteria rather than of Arthrospira, so per the scoring rules they live in the sourcing caveat, not here.
Side Effect Profile (1.6/5.0): Side effects are mild and infrequent. The most common is transient GI upset, including mild nausea, bloating, or loose stools when starting or at higher doses, which usually settles within days. Some people dislike the strong taste and smell of the powder. There is no consistent pattern of serious side effects in the randomized trials, and what does occur is dose-related and reversible. Starting low and building up over a week largely avoids the GI complaints.
Financial Cost (1.6/5.0): Spirulina is among the cheapest evidence-backed supplements, at roughly $10 to $25 per month for reputable powder or tablets at 3 to 5 g/day. Powder is cheaper per gram than tablets. The only cost worth paying up for is third-party testing, since a certified product is the difference between a benign food and a contamination risk. There is no meaningful brand-versus-generic premium beyond verified quality.
Time/Effort Burden (1.6/5.0): The effort is minimal. It is a once-daily dose with no cycling, timing rules, or stacking complexity, and it can be taken with or without food. The only friction is the taste of the powder, which most people solve by blending it into a smoothie or switching to tablets. There is no monitoring requirement beyond optionally checking the marker you are targeting.
Opportunity Cost (2.0/5.0): The modest opportunity cost is that spirulina's small per-marker effects can create a false sense that the cardiometabolic problem is handled, crowding out the lifestyle changes that drive most of the improvement. It does not interfere with exercise and stacks cleanly with other supplements and most medications. The honest caution is to treat it as an add-on to diet, activity, and prescribed therapy rather than a substitute, which keeps opportunity cost low but not negligible.
Dependency/Withdrawal (1.4/5.0): There is no dependency, tolerance, or withdrawal syndrome. Spirulina is a food, and stopping it produces no physiological withdrawal. The only thing that reverses on stopping is the benefit itself, as the cardiometabolic markers drift back toward baseline, which is a durability point rather than a withdrawal one. This places dependency at the floor.
Reversibility (1.4/5.0): Stopping spirulina is clean and immediate, with no taper required and no lasting changes. Because it is a dietary intervention with a short biological footprint, the effects simply fade and baseline returns. There are no permanent physiological changes attributable to the algae, which is why reversibility sits at the floor.
Is Spirulina worth it?
Spirulina earns a strong-recommend at 7.0 because it delivers a replicated cluster of cardiometabolic benefits at food-grade safety and an unusually low cost. The practical verdict: if you have elevated blood pressure, lipids, or fasting glucose, a certified spirulina product is a cheap, low-risk add-on worth a measured 12-week trial. If your markers are already optimal, expect little, and if you have phenylketonuria or active autoimmune disease, it is not for you. The score tier is justified by the breadth of meta-analytic support and the benign risk profile, tempered to moderate confidence because individual trials are small and antioxidant outcomes are mixed. The sourcing caveat is the whole game: the algae is safe, but uncertified product is not.
✅ Best for: People with elevated blood pressure who want a cheap evidence-backed adjunct, given the several-mmHg pooled effect in Machowiec 2021; people with high LDL or triglycerides looking for a food-grade lipid nudge; people with prediabetes or type 2 diabetes targeting fasting glucose specifically; cost-conscious supplement users who want a dense nutrient base of protein, iron, and carotenoids; allergic rhinitis sufferers willing to run a personal trial after Cingi 2008; and measurement-minded people who will pick one marker, dose for 12 weeks, and re-test.
❌ Avoid if: You have phenylketonuria, since spirulina contains phenylalanine and is contraindicated; you have active autoimmune disease such as lupus or rheumatoid arthritis, where immune stimulation could theoretically trigger a flare; you are pregnant or breastfeeding without clinician guidance; or you cannot verify your product. The contamination findings in Rhoades 2023 mean uncertified open-pond product can carry microcystins or heavy metals, so a current certificate of analysis showing microcystins below 1 ppm is mandatory, especially for children.
What is Spirulina best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Cardiovascular: 7.5/10
Score: 7.5/10Spirulina earns 7.5/10 for cardiovascular because the blood-pressure signal is real and replicated. Machowiec 2021 pooled 5 randomized trials in 230 subjects and found systolic pressure falling 4.59 mmHg and diastolic falling 7.02 mmHg, with the largest effect in people who started hypertensive. Shiri 2025, a GRADE-assessed meta-analysis, confirmed the direction with systolic down 4.41 mmHg and diastolic down 2.84 mmHg. Combined with consistent lipid improvement, this is a coherent cardiometabolic effect at a few grams a day. It is an adjunct to diet, exercise, and medication when indicated, not a replacement, but the magnitude is clinically meaningful for a cheap food.
Metabolic Health: 7.0/10
Score: 7.0/10Metabolic health scores 7.0/10 because spirulina improves several risk factors at once. Huang 2018 pooled 12 trials and reported fasting glucose down 5.01 mg/dL, triglycerides down 39.2 mg/dL, and diastolic pressure down 7.17 mmHg. The lipid and blood-pressure meta-analyses point the same way. This clustering of small benefits across glucose, lipids, and pressure is exactly what makes it useful for someone with early metabolic syndrome. The honest boundary is that each individual effect is modest, and these are surrogate markers, so pair it with the lifestyle work that drives the bulk of metabolic improvement.
Blood Sugar / Glycemic Control: 7.0/10
Score: 7.0/10Blood sugar scores 7.0/10 on the strength of glycemic meta-analyses. Hatami 2021 pooled 8 studies in type 2 diabetes and found fasting glucose dropping 17.88 mg/dL, although HbA1c did not move significantly. Ghanbari 2022 similarly found a significant fasting-glucose reduction with a non-significant HbA1c change. The takeaway is honest: spirulina nudges fasting glucose more reliably than it shifts longer-term HbA1c, so it suits someone targeting fasting numbers as one lever among diet, weight, and activity rather than as a standalone diabetes therapy.
Respiratory: 6.5/10
Score: 6.5/10Respiratory and allergy scores 6.5/10 on the strength of a single clean RCT. Cingi 2008 ran a double-blind placebo-controlled trial in allergic rhinitis and found spirulina significantly improving nasal discharge, sneezing, congestion, and itching versus placebo. That is a real, symptom-level outcome rather than a biomarker, which is why it lifts this subrating despite resting on one trial. The boundary is replication: one well-designed RCT is encouraging but not the same as a meta-analytic body, so treat allergic rhinitis as a promising off-core use worth a personal trial.
Body Composition / Fat Loss: 6.0/10
Score: 6.0/10Body composition scores 6.0/10 because the anthropometric meta-analyses are consistent but small in magnitude. Zarezadeh 2021 found body weight down 1.85 kg and waist circumference down 1.09 cm, with BMI moving only in trials lasting 12 weeks or more. Lak 2025, a GRADE-assessed dose-response meta-analysis of 17 RCTs, reported body weight down 1.07 kg, BMI down 0.40, and body fat down 0.84 percent. These are genuine pooled effects but a kilogram or two is a supporting role, useful alongside a calorie and training plan rather than as a fat-loss driver.
Anti-Inflammatory: 6.0/10
Score: 6.0/10Anti-inflammatory lands at 6.0/10 because the inflammation evidence is real but smaller than the cardiometabolic case. Shahraki Jazinaki 2025 pooled 7 trials in 283 subjects and found C-reactive protein falling 0.55 mg/L, a significant result. Mohiti 2021, however, found pooled malondialdehyde and IL-6 reductions that trended down but did not reach significance. So the CRP signal supports a moderate score while the oxidative-stress markers temper enthusiasm. Spirulina is a reasonable adjunct for someone tracking CRP, not a proven anti-inflammatory for harder endpoints.
Liver / Detoxification: 5.5/10
Score: 5.5/10Liver health scores 5.5/10 because the NAFLD signal is suggestive but thin. Mazloomi 2022 ran a randomized double-blind trial in 46 NAFLD patients using 20 g/day for 8 weeks and reported significant between-group improvement in ALT, AST, malondialdehyde, and total antioxidant capacity. That trial later received an Expression of Concern, so it is cited with that flag and not leaned on heavily. The honest read is that liver enzymes plausibly improve alongside the broader metabolic effect, but the dedicated human evidence is one flagged trial, so keep expectations modest.
Immune Function: 5.0/10
Score: 5.0/10Immune function scores 5.0/10 because the human evidence is indirect. Spirulina phycocyanin has antioxidant and immunomodulatory activity in mechanistic and animal work, and the Cingi 2008 allergic rhinitis RCT is the closest human immune-related outcome. There is no strong human trial base for infection resistance or vaccine response specific to spirulina. The score reflects plausible biology plus one allergy RCT, balanced against the autoimmune-flare caution that means immune modulation can cut both ways for the wrong person.
Energy / Fatigue: 5.0/10
Score: 5.0/10Energy and fatigue scores 5.0/10 on small exercise trials. Kalafati 2010 used a double-blind crossover in 9 trained men at 6 g/day for 4 weeks and found time to fatigue rising from 2.05 to 2.70 minutes with a 10.9 percent rise in fat oxidation. Lu 2006 reported extended time to exhaustion and lower exercise-induced oxidative damage. These are small, short studies in athletes, so the signal is real but modest and not yet a robust fatigue claim for the general user.
Endurance / Cardio: 5.0/10
Score: 5.0/10Endurance scores 5.0/10 for the same reason as energy. Kalafati 2010 found a meaningful rise in time to fatigue and fat oxidation in trained men, and Lu 2006 extended time to exhaustion while lowering oxidative-stress markers. Both are small double-blind trials, which is encouraging, but the total participant count is low and replication in larger or recreational populations is missing. Treat the ergogenic effect as a plausible bonus rather than a primary reason to supplement.
Antioxidant / Oxidative Stress: 5.0/10
Score: 5.0/10Antioxidant scores 5.0/10 because the pooled human data is mixed. Mohiti 2021 pooled 11 trials in 465 participants and found malondialdehyde reduction that did not reach significance, with IL-6 and TBARS trending down but non-significant. Individual exercise trials like Lu 2006 show lower oxidative markers, but the meta-analytic picture is inconsistent. Phycocyanin is a genuine antioxidant in vitro, yet the human outcome data does not yet justify a confident antioxidant claim, which keeps this at a middling score.
| Use Case | Score | Summary |
|---|---|---|
| ○ Healthspan | 4.5 | The cluster of blood-pressure, lipid, and glucose improvements supports a modest healthspan case, but it rests on surrogate markers rather than functional aging endpoints. |
| ○ Geriatric / Aging Population | 4.5 | Plausible for older adults given the cardiometabolic effects and complete protein, but dedicated trials in geriatric populations are sparse; sourcing caution matters more in vulnerable groups. |
| ○ Longevity / Lifespan | 4.0 | Indirect only. Cardiometabolic risk-factor improvement is consistent with healthier aging, but there are no human lifespan or hard-outcome trials for spirulina. |
| ○ Recovery / Repair | 4.0 | Lower exercise-induced oxidative damage in small trials like Lu 2006 suggests mild recovery support, but dedicated recovery endpoints are limited. |
| ○ Gut Health / Microbiome | 3.5 | Prebiotic and microbiome effects are mostly preclinical; human gut-outcome trials specific to spirulina are limited. |
| ○ Heavy Metal / Toxin Burden | 3.0 | Often marketed for detox, but human chelation evidence is weak. The bigger issue is that uncertified spirulina can itself carry heavy metals, so the detox framing is the opposite of reassuring. |
| ○ Kidney Function | 3.0 | Some animal nephroprotection data exists, but direct human renal-outcome evidence is lacking. |
| ○ Cognition / Focus | 3.0 | No meaningful human cognition trials for spirulina; any benefit would be indirect via metabolic and vascular health. |
| ○ Mood / Emotional Regulation | 3.0 | No direct mood or depression RCT base; mechanistic links through inflammation are speculative for this compound. |
| ○ Skin / Beauty | 3.0 | Carotenoid and antioxidant content gives a plausible skin rationale, but human skin-outcome trials are minimal. |
Frequently Asked Questions
What does spirulina actually do in the body?
Spirulina is dried Arthrospira algae packed with phycocyanin, gamma-linolenic acid, carotenoids, chlorophyll, and complete protein, and in humans it produces modest reductions in blood pressure, LDL, triglycerides, and fasting glucose. Machowiec 2021 pooled randomized trials showing systolic pressure down 4.59 mmHg and diastolic down 7.02 mmHg. Think of it as a nutrient-dense food that nudges several cardiometabolic markers, not a single-target drug.
How much spirulina should I take and when?
Most clinical benefit shows up at 1 to 8 g/day, with blood-pressure and lipid trials clustering at 1 to 4.5 g/day and glycemic or liver trials at 2 to 8 g/day. Timing is flexible; take it daily with or without food. Powder is cheapest but strong-tasting, while tablets let you count the dose. Give any target at least 8 to 12 weeks before judging, and track the relevant marker.
What does the human evidence on spirulina actually show?
The strongest human evidence is cardiometabolic. Meta-analyses show blood pressure falling several mmHg per Machowiec 2021, LDL down about 41 mg/dL and triglycerides down about 44 mg/dL per Serban 2016, and fasting glucose down about 18 mg/dL in type 2 diabetes per Hatami 2021. Allergy and exercise have single supportive RCTs. Antioxidant and inflammation results are mixed.
Is spirulina safe to take long-term?
Clean-sourced spirulina has a benign safety profile, with mild GI upset as the most common complaint, and it has a centuries-long food-use history. The real risk is extrinsic: open-pond product from uncertified producers can carry microcystins or heavy metals, as Rhoades 2023 documented in retail samples. The algae itself does not make those toxins. Buy from a producer with a current certificate of analysis.
Who should avoid spirulina?
Anyone with phenylketonuria should avoid spirulina because it contains phenylalanine. People with autoimmune conditions like lupus or rheumatoid arthritis should be cautious, since spirulina can stimulate immune activity and a theoretical flare cannot be ruled out. Pregnant or breastfeeding people should use it only under clinician guidance, and children need certified product given the contamination findings in Rhoades 2023.
Spirulina vs chlorella: which one should I choose?
Spirulina has the stronger human evidence base for cardiometabolic outcomes, with multiple meta-analyses on blood pressure, lipids, and glucose, while chlorella's human trials are fewer and more heterogeneous. Chlorella is promoted more for heavy-metal binding, though that evidence is weaker. If your goal is measurable blood-pressure, lipid, or glucose support, spirulina is the better-evidenced pick. Both share the same sourcing caution around contamination.
How fast does spirulina start working?
Plan on weeks, not days. The blood-pressure and lipid trials that establish the evidence ran roughly 6 to 12 weeks, and glycemic and liver trials used 8 to 12 weeks. Allergic rhinitis symptom relief in Cingi 2008 emerged over several weeks of daily use. There is no acute effect to feel on day one, so commit to a 12-week run and measure the marker you care about before and after.
How do I know my spirulina is not contaminated?
Demand a current certificate of analysis showing microcystins below 1 ppm and heavy metals within limits. Pinchart 2023 found over 99 percent of monitored production batches below the 1 ppm microcystin limit, but Rhoades 2023 found measurable microcystins in all five retail products tested. The toxins come from contaminant cyanobacteria in open ponds, not from Arthrospira itself, so producer quality control is everything.
What could change Spirulina's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
The most plausible upward move would come from large, long, independent randomized trials confirming the cardiometabolic effects on hard endpoints rather than surrogate markers, which would lift Efficacy and Evidence first. The most plausible downward move would be a documented intrinsic safety signal from clean product or evidence that the contamination problem is more widespread than current monitoring suggests, which would pull Safety and confidence. Because the current case rests on consistent meta-analytic direction with modest magnitudes, the score is more likely to firm up than to swing hard in either direction.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| Large independent RCT confirms blood-pressure and lipid effects on hard endpoints | Efficacy 3.3 to 3.9, Evidence 3.4 to 4.0 | 7.7 / 10 💪 Strong recommend |
| Industry-funding adjustment confirmed across the lipid and BP trial pool | Evidence 3.4 to 3.0 | 6.7 / 10 👍 Worth trying |
| Contamination shown to be widespread and hard to verify even in certified product | Safety 1.6 to 2.6, confidence to Low | 6.3 / 10 👍 Worth trying |
| Allergic rhinitis effect replicated in a second well-designed RCT | Breadth 3.7 to 3.9 | 7.2 / 10 💪 Strong recommend |
| Antioxidant and inflammation outcomes confirmed in newer meta-analyses | Breadth 3.7 to 4.0, Efficacy 3.3 to 3.5 | 7.4 / 10 💪 Strong recommend |
| A demonstrated intrinsic safety signal emerges from clean-sourced product | Safety 1.6 to 3.0, Side effects 1.6 to 2.2 | 5.9 / 10 👍 Worth trying |
Key Evidence Sources
- Machowiec et al. 2021 - Effect of Spirulina Supplementation on Systolic and Diastolic Blood Pressure: Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrients. 5 RCTs, 230 subjects: systolic down 4.59 mmHg, diastolic down 7.02 mmHg
- Shiri et al. 2025 - The Effect of Spirulina Supplementation on Blood Pressure in Adults: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Clinical Trials, Phytotherapy Research. Systolic WMD down 4.41 mmHg, diastolic down 2.84 mmHg
- Serban et al. 2016 - A systematic review and meta-analysis of the impact of Spirulina supplementation on plasma lipid concentrations, Clinical Nutrition. 7 RCTs: total cholesterol down 46.76, LDL down 41.32, triglycerides down 44.23 mg/dL
- Rahnama et al. 2023 - The effect of Spirulina supplementation on lipid profile: GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials, Pharmacological Research. 20 studies, 1076 participants: LDL, TC, and TG SMD around -0.6
- Hatami et al. 2021 - The effect of spirulina on type 2 diabetes: a systematic review and meta-analysis, Journal of Diabetes and Metabolic Disorders. 8 studies: fasting glucose down 17.88 mg/dL; HbA1c not significant
- Huang et al. 2018 - Quantifying the effects of spirulina supplementation on plasma lipid and glucose concentrations, body weight, and blood pressure: a systematic review and meta-analysis, Diabetes Metabolic Syndrome and Obesity. 12 trials: fasting glucose down 5.01 mg/dL, triglycerides down 39.2 mg/dL, diastolic down 7.17 mmHg
- Ghanbari et al. 2022 - Effect of Microalgae Arthrospira on Biomarkers of Glycemic Control and Glucose Metabolism: A Systematic Review and Meta-analysis, Current Problems in Cardiology. 7 studies: fasting blood sugar down 1.77 mg/dL; HbA1c not significant
- Cingi et al. 2008 - The effects of spirulina on allergic rhinitis, European Archives of Oto-Rhino-Laryngology. Double-blind RCT: significant improvement in nasal discharge, sneezing, congestion, itching
- Zarezadeh et al. 2021 - Spirulina supplementation and anthropometric indices: A systematic review and meta-analysis of controlled clinical trials, Phytotherapy Research. Body weight down 1.85 kg, waist down 1.09 cm
- Lak et al. 2025 - Effects of spirulina supplementation on body composition in adults: a GRADE-assessed and dose-response meta-analysis of RCTs, Nutrition and Metabolism. 17 RCTs: body weight down 1.07 kg, BMI down 0.40, body fat down 0.84 percent
- Mohiti et al. 2021 - Spirulina supplementation and oxidative stress and pro-inflammatory biomarkers: A systematic review and meta-analysis of controlled clinical trials, Clinical and Experimental Pharmacology and Physiology. 11 trials, 465 participants: malondialdehyde reduction non-significant
- Shahraki Jazinaki et al. 2025 - Effects of Spirulina Supplementation on C-Reactive Protein: A Systematic Review and Dose-Response Meta-Analysis, Food Science and Nutrition. 7 trials, 283 subjects: CRP down 0.55 mg/L
- Kalafati et al. 2010 - Ergogenic and antioxidant effects of spirulina supplementation in humans, Medicine and Science in Sports and Exercise. Double-blind crossover, 9 trained men: time to fatigue up, fat oxidation up 10.9 percent
- Lu et al. 2006 - Preventive effects of Spirulina platensis on skeletal muscle damage under exercise-induced oxidative stress, European Journal of Applied Physiology. Double-blind RCT: extended time to exhaustion, lower plasma malondialdehyde
- Mazloomi et al. 2022 - The effect of Spirulina sauce on cardiometabolic risk factors, oxidative stress biomarkers, glycemic profile, and liver enzymes in nonalcoholic fatty liver disease patients: A randomized double-blinded clinical trial, Food Science and Nutrition. RCT, 46 NAFLD patients, 20 g/day: ALT, AST, MDA, TAC improved. Expression of Concern issued 2025; cited with that flag.
- Pinchart et al. 2023 - Microcystins and Cyanobacterial Contaminants in the French Small-Scale Productions of Spirulina, Toxins. 623 samples, over 99 percent below the 1 ppm microcystin limit; toxins from contaminant cyanobacteria, not Arthrospira
- Rhoades et al. 2023 - Microbiota and Cyanotoxin Content of Retail Spirulina Supplements and Spirulina Supplemented Foods, Microorganisms. All 5 retail products contained microcystins, some above child intake limits; open-pond contamination
- Karkos et al. 2010 - Spirulina in Clinical Practice: Evidence-Based Human Applications, Evidence-Based Complementary and Alternative Medicine. Reviews spirulina's long history as a food, including reported use during the Aztec civilization, alongside clinical applications
What does the evidence say about Spirulina?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Machowiec 2021, Shiri 2025, Serban 2016, Rahnama 2023, Hatami 2021, Huang 2018, Shahraki Jazinaki 2025, Mohiti 2021
Traditional Medicine Systems
Confidence: Medium
Citations: Karkos 2010
Holistic Evidence for Spirulina
Centuries of safe food use across two cultures converge with modern randomized-trial evidence that spirulina modestly improves blood pressure, lipids, and fasting glucose, which together support a strong-recommend score for a cheap, low-risk whole food.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- LDL Cholesterol Pre | Expected Down
- Triglycerides During | Expected Down
- Fasting Glucose Pre | Expected Down
- ALT During | Expected Down
Pulse Dimensions to Watch
- Energy During | Expected Watch | Secondary
- Body During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Digestive comfort after dosing Scale 1-5 | During | Expected Watch
- Nasal and sinus symptoms (if allergy is the target) Scale 1-5 | During | Expected Up
Red Flags: Stop and Consult
- New or worsening autoimmune-flare symptoms (joint pain, rash, fatigue spikes); stop and consult a clinician
- Any use in phenylketonuria; spirulina contains phenylalanine and is contraindicated
- Persistent GI distress, dark urine, or jaundice, which could signal a contaminated product
Other interventions for Cardiovascular
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.285 − 0.712 = 1.573
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.573 / 4.00) × 5 = 7.0 / 10
